Andres Jose Maria Ferreri
0000-0001-9606-6124
14 papers found
Refreshing results…
Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update
Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial
Diagnosis and Treatment Using Autologous Stem-Cell Transplantation in Primary Central Nervous System Lymphoma: A Systematic Review
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms
ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL
Long‐lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B‐cell lymphoma who are not eligible for or failed autologous transplantation
Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma
Clarithromycin as a “repurposing drug” against MALT lymphoma
Missing publications? Search for publications with a matching author name.